Biotech Startups

Etiome develops stage-specific medicines by applying single-cell omics and artificial intelligence to map disease progression and identify disease-modifying targets at early biological inflection points for preemptive intervention. Founded in 2021 out of Flagship Pioneering's Preemptive Health and Medicine initiative, the biotech company focuses on treating or reversing disease before it advances to later stages.

1 investor

Euclises Pharmaceuticals develops oral, small-molecule drugs targeting COX-2 to disrupt the tumor microenvironment and enhance cancer cell death, particularly when combined with immune checkpoint inhibitors or EGFR inhibitors. The company is advancing these molecules through clinical trials to improve immuno-oncology therapies.

1 investor

1 investor

Tissue Targeting Therapies develops therapeutics targeting specific tissues using computational genomics and immunology. The company serves patients through drug development in the biotech/medtech space.

1 investor

Eureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell-based therapies to treat solid tumors and other cancers. Its pipeline is built on the ARTEMIS and E-ALPHA technology platforms aimed at targeting cancer-specific antigens.

1 investor

Eurofins Viracor is a clinical laboratory that develops and delivers diagnostic tests for infectious diseases, cellular function disorders, oncology, and transplant rejection monitoring. The company serves healthcare providers and patients in the United States through comprehensive laboratory services and biomarker research.

1 investor

Archimica is a contract manufacturer of active pharmaceutical ingredients (APIs), GMP building blocks and reagents, offering process development and production from clinical to large commercial scale for innovative and generic pharmaceutical companies. Operating from its Lodi site in Italy, it specializes in hazardous and difficult chemistry including anticancer APIs, and supplies customers across roughly 50 countries.

1 investor

Evaheart develops implantable and extracorporeal ventricular assist devices for heart failure and vascular disease treatment. The company manufactures medical devices and operates an integrated ecosystem including research, production, and clinical solutions.

1 investor

EVANIUM develops OPTISOLV®, an IP-protected drug-delivery technology that improves the water solubility, stability, absorption, and taste of plant-based active ingredients such as polyphenols and flavonoids. The technology is aimed at brands making food, nutraceutical, pharmaceutical, and personal care products, with development in Germany and production in Europe.

1 investor

Evec (株式会社イーベック) is a Japanese biotechnology company that develops fully human monoclonal antibodies through its research labs. The page is a corporate officers/executive profile page listing the company's board members and auditors.

1 investor

Evecxia Therapeutics develops 5-HTP-based drugs using proprietary drug delivery technologies designed to increase brain serotonin production as adjunctive treatments for depression and other mental disorders. Its therapies target patients with disabling mental illness not adequately treated by existing antidepressants such as SSRIs and SNRIs.

1 investor

Eveliqure develops a live attenuated vaccine platform for oral administration targeting Shigella and ETEC pathogens that cause diarrheal disease in travelers and populations in low- and middle-income countries. The company's lead product, ShigETEC, provides broad serotype-independent protection against multiple pathogens through targeted genetic mutations.

1 investor

1 investor

1 investor

Everest is an AI platform that automates regulatory, clinical, and commercial document workflows for pharmaceutical, medtech, and contract research organizations (CROs), generating submission-ready documents and associated statistical analyses from source data.

1 investor

Evergreen Theragnostics manufactures radiopharmaceutical therapeutics and diagnostics for cancer treatment and develops novel radiotherapeutic agents for cancer patients. The company offers high-quality manufacturing services and handles product registration and commercialization for partner companies.

1 investor

Evergreen produces cultivated beef intended to be blended with traditional beef (at 10–50%) to help food producers manage costs and reduce exposure to cattle-price volatility. Its cultivated meat is made without added antibiotics, hormones, growth factors, or plant fillers and is designed to match the taste and texture of conventional beef.

1 investor

1 investor

EVerMed is a company focused on extracellular vesicle biology and pharmaceutical development, combining academic expertise with industry experience in drug development and regenerative medicine.

1 investor

EVERSANA is an independent provider of integrated commercial services to the life sciences industry, supporting products across all stages of their life cycle. It serves over 670 organizations, including startups and established pharmaceutical companies, addressing the needs of patients, prescribers, channel partners and payers.

1 investor

eversyn produces human milk oligosaccharides and nucleotide sugars using proprietary cell-free biocatalytic technology for food and nutrition applications. The company emerged from the Max Planck Institute Magdeburg as a spin-out translating enzyme and bioprocess research into commercial production.

1 investor

EVerZom develops exosome formulation technologies that modify cells to release exosomes with enhanced therapeutic properties, designed for targeted delivery to specific tissue sites. The company creates formulated exosome drugs for treating pathologies through local or systemic administration routes.

1 investor

Evestia Clinical is a clinical research organization providing clinical trial services for biotech companies across oncology, rare disease, neurology, immunology, and inflammation. The company was established in 1996 and recently rebranded to reflect its expanded focus as a global clinical research provider.

1 investor

EviCure is a pre-clinical biopharmaceutical company developing extracellular vesicle-based therapies for cancer treatment using AI and disease modeling. The company uses AI-powered platforms to identify EV subpopulations with therapeutic potential and enables targeted drug delivery for oncology applications.

1 investor